
E 6130
CAS No. 1427058-33-0
E 6130( E-6130 | E6130 )
Catalog No. M11803 CAS No. 1427058-33-0
A potent, selective, orally available CX3C chemokine receptor 1 (CX3CR1) modulator that inhibits the fractalkine-induced chemotaxis of human peripheral blood NK cells with IC50 of 4.9 nM.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 401 | Get Quote |
![]() ![]() |
50MG | 1674 | Get Quote |
![]() ![]() |
100MG | 2493 | Get Quote |
![]() ![]() |
200MG | Get Quote | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameE 6130
-
NoteResearch use only, not for human use.
-
Brief DescriptionA potent, selective, orally available CX3C chemokine receptor 1 (CX3CR1) modulator that inhibits the fractalkine-induced chemotaxis of human peripheral blood NK cells with IC50 of 4.9 nM.
-
DescriptionA potent, selective, orally available CX3C chemokine receptor 1 (CX3CR1) modulator that inhibits the fractalkine-induced chemotaxis of human peripheral blood NK cells with IC50 of 4.9 nM; shows no significant agonistic or antagonistic activity (EC50 and IC50>10 uM) for any other chemokine receptors; induces the down-regulation of CX3CR1 on the cell surface of CD56+ NK cells with IC50 of 5.2 nM, shows agonistic activity with respect to [35S]GTPγS binding (EC50=133 nM) and β-arrestin recruitment (EC50=2.4 uM) in CX3CR1-expressing CHO-K1 membrane; inhibits the migration of CX3CR1+ immune cells, and ameliorates several inflammatory bowel disease-related parameters in murine CD4+CD45RBhigh T-cell-transfer colitis model.Solid Tumors Phase 1 Clinical.
-
In VitroE6130 is an orally active and highly selective CX3CR1 modulator, inhibits the fractalkine-induced chemotaxis of human peripheral blood natural killer cells (IC50, 4.9 nM), and down-regulates CX3CR1 on the cell surface of CD56+ NK cells with an EC50 value of 5.2 nM. E6130 also shows agonistic activity via CX3CR1 with respect to GTPγS binding (EC50 = 133 nM) and β-arrestin recruitment (EC50 = 2.4 μM) in CX3CR1-expressing CHO-K1 membrane but show no antagonistic activity.
-
In VivoE6130 (10 or 30 mg/kg, p.o.) reduces several inflammatory bowel disease-related parameters in a murine CD4+ CD45RBhigh T-cell-transfer colitis model and a murine oxazolone-induced colitis model.
-
SynonymsE-6130 | E6130
-
PathwayGPCR/G Protein
-
TargetChemokine Receptor
-
RecptorChemokine Receptor
-
Research AreaCancer
-
IndicationSolid Tumors
Chemical Information
-
CAS Number1427058-33-0
-
Formula Weight556.067
-
Molecular FormulaC28H37ClF3N3O3
-
Purity>98% (HPLC)
-
SolubilityDMSO : ≥ 250 mg/mL 449.59 mM
-
SMILESCC1CN(CC1(CC(=O)O)C(=O)NC2CCN(CC2)CC3=CCCCC3)CC4=C(C=CC=C4Cl)C(F)(F)F
-
Chemical Name[(3S,4R)-1-[2-Chloro-6-(trifluoromethyl)benzyl]-3-{[1-(cyclohex-1-en-1-ylmethyl)piperidin-4-yl]carbamoyl}-4-methylpyrrolidin-3-yl]acetic acid (2S)-hydroxy(phenyl)
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Wakita H, et al. Mol Pharmacol. 2017 Nov;92(5):502-509.
molnova catalog



related products
-
CCR2-RA-[R]
A potent, selective, allosteric CCR2 antagonist with IC50 of 103 nM.
-
INCB9471
A potent, selective and orally bioavailable CCR5 antagonist IC50 of 6.5 nM, Kd of 3.1 nM in human PBMCs.
-
SB 265610
A potent, selective, reversible CXCR2 antagonist with with Kd of 3.48 nM.